Investment Overview

Home / Investor Relations / Investment Overview


  • Robust product pipelines addressing multiple large market opportunities
  • Highly experienced executive and scientific team
  • GMP-certified facilities in the PRC designed to international, U.S. FDA standards, and Chinese regulatory bodies’ standards
  • The first cellular medicine company in China accredited with IS0 (International Standards Organization) 9001:2008 certification by internationally recognized quality management system SGS

Our strategy is to commercialize both home grown and partnered cellular medicine technologies in a safe and efficient manner, and achieve a leading position in the China specialty pharmaceutical market for cell therapeutics.  Our near term objective is to pursue successful clinical trials in China for our Stem Cell and Immuno-Oncology applications.  By applying U.S. Standard Operating Procedures (SOPs) and protocols and following authorized treatment plans in China we are differentiated with a first mover’s advantage and a fortified barrier to entry from competitors.

We believe that few competitors in China are as well-equipped as we are in the clinical trial development, diversified U.S. FDA protocol compliant manufacturing facilities, regulatory compliance and policy making participation, as well as a long-term presence in the U.S. with U.S.-based management and investor base.

We intend to continue our business development effort by adding other proven domestic and international biotechnology partners to monetize the China health care market.